The Chemours Company (CC) — ESG & Values Scores

Environment story

Chemours faces substantial environmental liabilities and regulatory challenges that materially depress the environmental pillar score. The company carries $618 million in environmental remediation liabilities as of December 31, 2025, with $88 million current. Major PFAS contamination legacies persist at multiple sites (Fayetteville, Washington Works, Dordrecht); the company recorded $93 million in environmental charges in 2025 alone, primarily for remediation reserve changes at sites covered by the New Jersey settlement. The company has not publicly disclosed comprehensive Scope 1, 2, or 3 greenhouse-gas emissions data or a specific net-zero target year in the 10-K filing, triggering automatic deductions. While the company participates in a binding Memorandum of Understanding (MOU) with DuPont, Corteva, and EID for cost-sharing of legacy PFAS liabilities (capped at $4 billion aggregate with ~$1.3 billion remaining post-settlements), this arrangement suggests reactive remediation rather than proactive decarbonization. The company reports ongoing capital expenditures for environmental compliance but does not specify renewable-energy transitions or direct operational decarbonization projects. Litigation-related and environmental charges totaled $413 million in 2025, indicating unresolved legacy contamination rather than forward-looking climate strategy.

Criticisms on file

PFAS Contamination Litigation and Settlements (New Jersey, Ohio, Delaware, Hoosick Falls)
Source: CC 10-K Note 22 Commitments and Contingent Liabilities; MD&A Litigation-related charges line item ($270M NJ settlement, $14M Hoosick Falls settlement, $13M Delaware supplemental payment accrual)
Washington Works Operational Disruption (January 2026) - Equipment damage from August 2025 utility outage; complex fluoropolymer supply-chain disruption expected to cost $20-25M in Q1 2026
Source: CC 10-K Recent Developments section
Fayetteville Site Environmental Remediation Ongoing - $46 million of $88 million current environmental liabilities relate to Fayetteville site; included in New Jersey settlement
Source: CC 10-K MD&A Liquidity and Capital Resources, Environmental remediation section; Note 22
Undisclosed Greenhouse Gas Emissions and No Public Net-Zero Target
Source: Absence from CC 10-K filing (comprehensive Scope 1, 2, 3 emissions and net-zero target year not disclosed in provided MD&A or financial notes)

Disclosed initiatives

PFAS Settlement with State of New Jersey

In August 2025, Chemours and co-defendants (DuPont, Corteva, EID) reached a Judicial Consent Order with the State of New Jersey requiring scheduled annual settlement payments totaling $875 million over 25 years. Chemours' share: $270 million net present value as of December 31, 2025. Expected funding: $150 million from PFAS Insurance MOU plus $50 million from MOU escrow through at least 2030.

Addresses legacy PFAS drinking-water contamination but represents remediation of past harm rather than emissions reduction or climate mitigation.
Environmental Remediation Reserves and MOU Cost-Sharing

Chemours maintains $618 million in environmental remediation liabilities with binding cost-sharing agreement capping its share of future legacy PFAS liabilities at 50% of costs (up to $4 billion aggregate cap). Approximately $1.3 billion remains available after recent settlement payments.

Structured liability management but reflects reactive posture to contamination legacies; no evidence of proactive net-zero or renewable-transition targets.
Capital Expenditures for Environmental Compliance

Total capital expenditures: $213 million in 2025 vs. $360 million in 2024. Company notes ongoing capital requirements to comply with environmental regulations and maintain site integrity and safety. No segment-level breakdown of pure environmental vs. operational capex disclosed.

Compliance spending does not substitute for operational decarbonization or renewable-energy transition metrics.

Social story

Chemours' social pillar score reflects incomplete disclosed data on workforce diversity, CEO-to-worker pay ratios, and labor relations. The 10-K does not provide explicit CEO-to-median-worker pay ratios, leadership diversity percentages, or documented union-standing metrics. The company recorded $270 million in litigation charges for the New Jersey PFAS settlement in 2025, alongside $14 million for Hoosick Falls class-action resolution and $18 million for asbestos/production-liability reserves, suggesting historical product-safety and worker-protection challenges. No evidence of active union-suppression activities or major strikes in the last 24 months is disclosed; however, the absence of positive union-cooperation statements or neutrality agreements also suggests a neutral rather than supportive labor posture. The company participates in supply-chain finance arrangements but does not disclose third-party audits of supplier labor practices or conflict-mineral policies. Workforce turnover rates are not provided in the filing.

Criticisms on file

New Jersey PFAS Settlement - $270 million accrual (Chemours share) for public water-system contamination linked to legacy manufacturing practices
Source: CC 10-K Note 22; MD&A Litigation-related charges ($270M recognized in 2025)
Undisclosed CEO-to-Median-Worker Pay Ratio and Leadership Diversity Metrics
Source: Absence from CC 10-K filing (no EEO-1 data, pay-equity, or board/executive diversity disclosed in provided document sections)
Asbestos and Production Liability Claims ($18 million accrual in 2025)
Source: CC 10-K MD&A Corporate and Unallocated Items, Litigation-related charges footnote (5)

Disclosed initiatives

Hoosick Falls Class Action Settlement (June 2025)

Chemours reached an agreement in principle to resolve the Hoosick Falls class-action lawsuit. Chemours' portion per MOU: $13.5 million total, with $11 million expected to be paid within 12 months and remaining $2.5 million in five annual installments.

Addresses legacy product-liability claims (PFOA contamination) but does not evidence forward-looking workforce protections or labor standards improvements.
Asbestos and Production Liability Reserves

Company accrued $18 million in 2025 related to asbestos and production-liability matters, indicating ongoing legacy claims management.

Reactive risk management; does not evidence proactive occupational health or supply-chain auditing.
Supply Chain Financing Programs

Company utilizes supply-chain financing with multiple third-party financial institutions and participates in customer early-pay programs. In 2025, accelerated collection of $414 million of accounts receivable via customer-facilitated programs with $6 million discount cost.

Working-capital management tool; no disclosed labor-standards audit or responsible-supplier framework.

Governance story

Chemours' governance score is depressed by substantial litigation and regulatory fines totaling $413 million in 2025 (litigation-related charges $320M plus environmental charges $93M), active PFAS class-action resolutions, and unresolved legacy-contamination liabilities. The company does not disclose board independence percentages, dual-class voting structures, or specific lobbying expenditures targeting environmental deregulation in the provided 10-K sections. However, the company operates under binding cost-sharing MOUs (DuPont, Corteva, EID) and faces tightening debt covenants: Moody's affirmed Ba3 rating with negative outlook (August 2025); S&P affirmed BB- with negative outlook (April 2025). The company has revised debt-maturity profiles multiple times (May, October 2025 amendments), signaling active liability management but also financial stress. The company reported a net loss of $(386) million in 2025 vs. $69 million net income in 2024, driven largely by litigation reserves and tax-valuation allowances ($181 million deferred-tax provision). No evidence of shareholder litigation blocks, PAC contributions, or trade-association climate-misalignment statements is provided in the 10-K; however, the absence of affirmative governance transparency on these matters and the scale of unresolved legal/environmental liabilities warrant a below-midpoint governance score.

Criticisms on file

Material Litigation and Environmental Liabilities - $618 million environmental reserves, $484 million litigation accrual as of December 31, 2025
Source: CC 10-K Note 22 Commitments and Contingent Liabilities; Balance Sheet; MD&A Liquidity section
Negative Credit Rating Outlooks - Moody's Ba3 (negative, August 2025); S&P BB- (negative, April 2025) reflecting financial stress
Source: CC 10-K MD&A Liquidity and Capital Resources section
Net Loss of $(386) million in 2025 driven by litigation reserves ($270M NJ settlement), environmental charges ($93M), and tax-valuation allowance ($181M)
Source: CC 10-K Consolidated Statements of Operations; MD&A Results of Operations; Note 9 Income Taxes
Undisclosed Board Independence, Dual-Class Voting Structure, and Lobbying Expenditures
Source: Absence from CC 10-K provided sections

Disclosed initiatives

Binding Memorandum of Understanding (MOU) - PFAS Cost-Sharing

Chemours, DuPont, Corteva, EID entered into binding MOU (January 2021) establishing 50-50 cost-split for legacy PFAS liabilities up to $4 billion aggregate cap. Approximately $1.3 billion remains available post-settlements. PFAS Insurance MOU (September 2023) allows suspension of annual $50 million escrow funding upon receipt of insurance proceeds.

Structured governance of multi-party contingent liabilities; demonstrates commitment to legal obligation management but does not address root environmental or product-safety governance improvements.
Debt Covenant Amendments (May & October 2025)

Amendment No. 3 (May 2025): Increased net-leverage-ratio thresholds, extended revolving-commitment maturity to May 2, 2030, raised aggregate revolving commitments to $1,000 million. Amendment No. 4 (October 2025): Extended $1,050 million Dollar Term Loan maturity from August 2028 to October 2032; adjusted margin to SOFR +3.50% (or base +2.50%).

Proactive refinancing to improve near-term maturity profile; reflects lender oversight and financial discipline but indicates prior debt stress.
Audit Committee Internal Review and Compliance Oversight

Company incurred ~$20 million in audit-committee internal-review costs in 2025 (decrease from 2024), indicating active governance review mechanism.

Internal audit/governance infrastructure present; insufficient detail provided on findings or remediation.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of The Chemours Company. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open The Chemours Company in the app for interactive charts and portfolio building.

More in Basic Materials

Linde plc (LIN) Southern Copper Corporation (SCCO) Newmont Corporation (NEM) Freeport-McMoRan Inc. (FCX) The Sherwin-Williams Company (SHW) Ecolab Inc. (ECL)